A comprehensive measure of Golgi sphingolipid flux using NBD C6-ceramide: evaluation of sphingolipid inhibitors
Journal of Lipid Research · 2024
DOI: 10.1016/j.jlr.2024.100584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von Allen H Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Stony Brook University, Stony Brook, NY, USA. Hauptthemen laut MEDLINE: Golgi Apparatus, Ceramides, Sphingolipids, Glucosyltransferases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Measurements of sphingolipid metabolism are most accurately performed by LC-MS. However, this technique is expensive, not widely accessible, and without the use of specific probes, it does not provide insight into metabolic flux through the pathway. Employing the fluorescent ceramide analogue NBD-C6-ceramide as a tracer in intact cells, we developed a comprehensive HPLC-based method that simultaneously measures the main nodes of ceramide metabolism in the Golgi. Hence, by quantifying the conversion of NBD-C6-ceramide to NBD-C6-sphingomyelin, NBD-C6-hexosylceramides, and NBD-C6-ceramide-1-phosphate (NBD-C1P), the activities of Golgi resident enzymes sphingomyelin synthase 1, glucosylceramide synthase, and ceramide kinase (CERK) could be measured simultaneously. Importantly, the detection of NBD-C1P allowed us to quantify CERK activity in cells, a usually difficult task. By applying this method, we evaluated the specificity of commonly used sphingolipid inhibitors and discovered that 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, which targets glucosylceramide synthase, and fenretinide (4HPR), an inhibitor for dihydroceramide desaturase, also suppress CERK activity. This study demonstrates the benefit of an expanded analysis of ceramide metabolism in the Golgi, and it provides a qualitative and easy-to-implement method.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
- Department of Physiology and Biophysics, Stony Brook University, Stony Brook, NY, USA.
- Department of Pathology, Stony Brook University, Stony Brook, NY, USA.
- Department of Medicine, Stony Brook University, Stony Brook, NY, USA; Department of Pathology, Stony Brook University, Stony Brook, NY, USA; Department of Medicine, The Northport Veterans Affairs Hospital, Northport, NY…
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Lee, A. H., Snider, J. M., Moorthi, S., Coant, N., Trayssac, M., Canals, D., Clarke, C. J., Luberto, C., & Hannun, Y. A. (2024). A comprehensive measure of Golgi sphingolipid flux using NBD C6-ceramide: evaluation of sphingolipid inhibitors. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100584
Vancouver
Lee AH, Snider JM, Moorthi S, Coant N, Trayssac M, Canals D, et al. A comprehensive measure of Golgi sphingolipid flux using NBD C6-ceramide: evaluation of sphingolipid inhibitors. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2024.100584
BibTeX
@article{Lee2024,
author = {Lee, Allen H and Snider, Justin M and Moorthi, Sitapriya and Coant, Nicolas and Trayssac, Magali and Canals, Daniel and Clarke, Christopher J and Luberto, Chiara and Hannun, Yusuf A},
title = {A comprehensive measure of Golgi sphingolipid flux using NBD C6-ceramide: evaluation of sphingolipid inhibitors},
journal = {Journal of Lipid Research},
year = {2024},
doi = {10.1016/j.jlr.2024.100584}
}
EUVIMED